Send to

Choose Destination

See 1 citation found by title matching your search:

J Alzheimers Dis. 2011;26(3):441-5. doi: 10.3233/JAD-2011-110350.

Anti-ATP synthase autoantibodies from patients with Alzheimer's disease reduce extracellular HDL level.

Author information

Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.


Aside from being an integral protein involved in the synthesis and hydrolysis of ATP, Ecto-F1-ATPase plays a role in cholesterol homeostasis. We demonstrated the presence of autoantibodies to ecto-F1-ATPase (ASabs) in sera and cerebrospinal fluids from patients with Alzheimer's disease (AD). Herein we show that ASabs, unlike irrelevant antibodies, can increase cellular uptake of HDL, a risk factor for the development of AD, via a mechanism involving the prototypical function of ecto-F1-ATPase: the generation of ADP due to the hydrolysis of ATP. Piceatannol, a specific inhibitor ecto-F1-ATPase, completely hindered these effects. We hypothesize that ASabs could exert a pathogenetic role in AD.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center